Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxycycline in Relapsed CTCL
NCT02341209Phase 2Terminated
- Sponsor
- Rochester General Hospital
- Start
- Feb 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxycycline in cutaneous T-cell lymphoma (CTCL), sponsored by Rochester General Hospital. Primary endpoint: Overall Response Rate at 1 year. Started Feb 2018; status: terminated.
02
Drugs
doxycycline
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT02341209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341209.